When will pagoclone be available for the stutterers?
I saw videos about pagoclone that dates support from 2007. So im checking now to see if that pill is available. Can anyone tell me when is it going to be out? Or is it still in the Phase III trial??
Answers:
(1). On March 30, 2002, at 12:19:29 posted by Anna M.
: Pagoclone availability?
It seem Pagoclone is currenty in Phase III trials. This looks like it might be a good med for frenzy disorder and anxiety.
http://www.dr-bob.org/babble/20020327/ms…
(2). Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced that results from the Company's Phase II EXPRESS trial for pagoclone in persistent developmental stuttering will be presented today at the 47th annual meeting of the New Clinical Drug Evaluation Unit (NCDEU), sponsored by National Institute for Mental Health (NIMH) and self held in Boca Raton, Florida. In addition, the presentation will include data from the first three months...
INDEVUS ANNOUNCES PROMISING PHASE II DATA FOR PAGOCLONE IN STUTTERING
(3). LEXINGTON, MA, May 24, 2006 – Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced top file results from the Company’s Phase II clinical trial for pagoclone in persistent developmental stuttering. Results from the trial show that pagoclone produces a statistically significant benefit in multiple primary and lower endpoints compared to placebo. Additionally, pagoclone produced either numerically superior improvement or trends for significant improvement on virtually adjectives other primary and secondary endpoints when compared to placebo. Pagoclone was also shown to be well tolerated and not associated near any serious adverse events.
http://thestutteringbrain.blogspot.com/2…
Finally : A product known as pagoclone xr for stuttering is at an advanced stage in trials and it is believed that it has the potential to bring much-needed nouns to those patients affected by this disorder. Pagoclone xr for stuttering is a novel, non-benzodiazepine member, of the cyclopyrrolone class of compounds and act as a gamma amino butyric acid (GABA) partial agonist. In clinical studies in anxiety disorders, it has be shown to reduce the symptoms of panic and generalised anxiety without cause the sedation or withdrawal effects, seen with benzodiazepine agents. It is contained that pagoclone xr for stuttering increases the action of GABA in the brain and thus has the dimensions to possibly reduce excess neuronal activity and the severity of persistent developmental stuttering. In the on-going trials of pagoclone xr for stuttering, functional brain imaging assessments enjoy been collected and sent to clinical centres for evaluation. Initial signs are therefore tremendously encouraging, indeed, during research it was noted that some voluntary patients who received pagoclone xr for stuttering, reported a dramatic reduction in their stuttering condition, but after discontinuation of treatment the stuttering returned to pre-study level. Source(s): http://www.suffering-stuttering.com/Pago…
Related Questions:
How does carbonmonoxide mete out blood clots?
Why does rigidity headache pills hold caffeine contained by it?
Do you agree that our medical research have be an abject and complete letdown contained by jargon of diseases cured?
Answers:
(1). On March 30, 2002, at 12:19:29 posted by Anna M.
: Pagoclone availability?
It seem Pagoclone is currenty in Phase III trials. This looks like it might be a good med for frenzy disorder and anxiety.
http://www.dr-bob.org/babble/20020327/ms…
(2). Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced that results from the Company's Phase II EXPRESS trial for pagoclone in persistent developmental stuttering will be presented today at the 47th annual meeting of the New Clinical Drug Evaluation Unit (NCDEU), sponsored by National Institute for Mental Health (NIMH) and self held in Boca Raton, Florida. In addition, the presentation will include data from the first three months...
INDEVUS ANNOUNCES PROMISING PHASE II DATA FOR PAGOCLONE IN STUTTERING
(3). LEXINGTON, MA, May 24, 2006 – Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced top file results from the Company’s Phase II clinical trial for pagoclone in persistent developmental stuttering. Results from the trial show that pagoclone produces a statistically significant benefit in multiple primary and lower endpoints compared to placebo. Additionally, pagoclone produced either numerically superior improvement or trends for significant improvement on virtually adjectives other primary and secondary endpoints when compared to placebo. Pagoclone was also shown to be well tolerated and not associated near any serious adverse events.
http://thestutteringbrain.blogspot.com/2…
Finally : A product known as pagoclone xr for stuttering is at an advanced stage in trials and it is believed that it has the potential to bring much-needed nouns to those patients affected by this disorder. Pagoclone xr for stuttering is a novel, non-benzodiazepine member, of the cyclopyrrolone class of compounds and act as a gamma amino butyric acid (GABA) partial agonist. In clinical studies in anxiety disorders, it has be shown to reduce the symptoms of panic and generalised anxiety without cause the sedation or withdrawal effects, seen with benzodiazepine agents. It is contained that pagoclone xr for stuttering increases the action of GABA in the brain and thus has the dimensions to possibly reduce excess neuronal activity and the severity of persistent developmental stuttering. In the on-going trials of pagoclone xr for stuttering, functional brain imaging assessments enjoy been collected and sent to clinical centres for evaluation. Initial signs are therefore tremendously encouraging, indeed, during research it was noted that some voluntary patients who received pagoclone xr for stuttering, reported a dramatic reduction in their stuttering condition, but after discontinuation of treatment the stuttering returned to pre-study level. Source(s): http://www.suffering-stuttering.com/Pago…
Related Questions: